World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
New Drug Sharply Lowers Cholesterol, but It’s Costly
Keywords:
Tags: Pharmaceutical,
Cholesterol lowering drug Praluent from Sanofi and Regeneron Pharmaceuticals in 2015
07/24/2015
Treatment with the drug is priced high at $14650 for a year. The alternative statin drugs are available for a few dollars. This drug would benefit patients not able to control their cholesterol using existing drugs. The FDA has approved the drug.
Grouped Articles
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
New Drug Sharply Lowers Cholesterol, but It’s Costly
New York Times 07/24/2015
Regeneron Pharmaceuticals strategies
07/24/2015
Grouped Articles
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
New Drug Sharply Lowers Cholesterol, but It’s Costly
New York Times 07/24/2015
Sanofi strategies
04/09/2010
Grouped Articles
Sanofi Expands Diabetes Efforts With Licensing Deal
Wall Street Journal 04/09/2010
Rivals Threaten to Crowd Out Novo in Expanding Diabetes Market
Wall Street Journal 08/25/2013
Sanofi's MS Drug Lemtrada Receives Approval in Europe
Wall Street Journal 09/17/2013
Sanofi Buys TargeGen, Boosting Oncology Pipeline
Wall Street Journal 07/01/2010
Sanofi Makes Public a $18.5 Billion Bid for Genzyme
New York Times 08/29/2010
Sanofi Fires CEO as Tensions Boil Over
Wall Street Journal 10/30/2014
Regeneron Pharmaceuticals performance
07/24/2015
Grouped Articles
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
New Drug Sharply Lowers Cholesterol, but It’s Costly
New York Times 07/24/2015
Sanofi performance
08/29/2010
Grouped Articles
Rivals Threaten to Crowd Out Novo in Expanding Diabetes Market
Wall Street Journal 08/25/2013
Sanofi's MS Drug Lemtrada Receives Approval in Europe
Wall Street Journal 09/17/2013
Sanofi Makes Public a $18.5 Billion Bid for Genzyme
New York Times 08/29/2010
Sanofi Fires CEO as Tensions Boil Over
Wall Street Journal 10/30/2014
Sanofi Fires Its Chief Executive but Retains His Global Strategy
New York Times 10/29/2014
Sticking Point: Sanofi’s Diabetes Franchise Is Crucial to Sorting Out a Mess
Wall Street Journal 11/07/2014
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us